J&J/Merck Bolsters Heartburn Lineup With Maximum Strength Pepcid AC
This article was originally published in The Tan Sheet
Executive Summary
New heartburn prevention/relief product Maximum Strength Pepcid AC will hit shelves Oct. 17, following FDA approval of the new dosage Sept. 24, according to Johnson & Johnson/Merck
You may also be interested in...
Pfizer Looks To Give J&J/Merck Heartburn With Zantac 150 Switch
Pfizer Consumer Healthcare's Rx-to-OTC switch of Zantac 150 appears to be a belated attempt to counter Johnson & Johnson/Merck's approval of Maximum Strength Pepcid AC last year
J&J, Schering OTC Advertising Outpaced DTC Spending In 2003
Johnson & Johnson spent approximately 40% more on OTC drug advertising in the first nine months of 2003 than on direct-to-consumer prescription drug advertising
Rolaids Line Expands Into Gas Relief With Multi-Symptom Extension
Pfizer is positioning new Rolaids Multi-Symptom line extension as handling gas as well as heartburn in comparison to GlaxoSmithKline's Tums in spots that broke November 17